{"id":"nct:NCT07368803","kind":"trial","title":"Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection","authors":["Yifan Wang"],"author_count":1,"year":2026,"published":"2026-01-27","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07368803","source_url":"https://clinicaltrials.gov/study/NCT07368803","archive_url":"https://space-kitty.com/papers/nct:NCT07368803","updated":"2026-02-03","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The primary objective of this study is to evaluate the safety of iNeo-Vac-R01, an individualized mRNA therapeutic technology based on tumor neoantigens, for the adjuvant treatment of patients with biliary malignant tumors after radical resection.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Biliary Malignant Tumors"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"sponsor":"Yifan Wang","conditions":["Biliary Malignant Tumors"],"interventions":["BIOLOGICAL: iNeo-Vac-R01"],"start_date":"2025-09-11","start_date_type":"ACTUAL","primary_completion_date":"2027-09-30","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}